Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Merck : Morgan Stanley Adjusts Price Target on Merck & Company to $88 From $85, Maintains Equal-Weight Rating

10/12/2021 | 09:43am EST


© MT Newswires 2021
All news about MERCK & CO., INC.
11/26New Analysis Shows Merck COVID-19 Pill Molnupiravir Less Effective Than Previously Repo..
MT
11/26Merck & Co. Says Molnupiravir Cuts Risk of Severe COVID-19 Based on Trial Data
MT
11/26Merck, Ridgeback Biotherapeutics' Molnupiravir Drug Reduced Risk of Severe COVID-19 Bas..
MT
11/26Merck and Ridgeback Biotherapeutics Provide Update on Results from MOVe-OUT Study of Mo..
BU
11/26UK To Test Merck & Co.'s COVID-19 Pill In National Study
MT
11/26Pfizer, Merck Reportedly Agree to License Production of Respective Experimental COVID-1..
MT
11/26Pfizer, Merck & Co. Set to Allow Vietnamese Companies to Produce COVID-19 Pill
MT
11/24Truist Securities Adjusts Merck's Price Target to $95 From $92, Reiterates Buy Rating
MT
11/24Merck to Present at the 4th Annual Evercore ISI HealthCONx Conference
BU
11/24Gilead Sciences, Merck Pause Phase 2 HIV Trial
MT
More news
Analyst Recommendations on MERCK & CO., INC.
More recommendations
Financials (USD)
Sales 2021 48 600 M - -
Net income 2021 13 638 M - -
Net Debt 2021 20 562 M - -
P/E ratio 2021 16,3x
Yield 2021 3,28%
Capitalization 200 B 200 B -
EV / Sales 2021 4,54x
EV / Sales 2022 3,78x
Nbr of Employees 73 500
Free-Float 70,5%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Last Close Price 79,16 $
Average target price 96,70 $
Spread / Average Target 22,2%
EPS Revisions
Managers and Directors
Robert M. Davis President, Chief Executive Officer & Director
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Kenneth C. Frazier Executive Chairman
Sandy Tremps Vice President-R&D IT CIO
Dave Williams Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
MERCK & CO., INC.-3.23%199 954
JOHNSON & JOHNSON1.82%419 109
ROCHE HOLDING AG16.05%336 162
PFIZER, INC.46.70%303 095
NOVO NORDISK A/S67.00%247 254
ELI LILLY AND COMPANY54.21%236 049